Change search
ReferencesLink to record
Permanent link

Direct link
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis: Results from the TYNERGY Trial: A Study in the Real Life Setting
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Show others and affiliations
2013 (English)In: PLoS ONE, ISSN 1932-6203, Vol. 8, no 3, e58643- p.Article in journal (Refereed) Published
Abstract [en]

Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue. In this one-armed clinical trial including 195 MS patients, natalizumab was prescribed in a real-life setting, and a validated questionnaire, the Fatigue Scale for Motor and Cognitive functions (FSMC), was used both before and after 12 months of treatment to evaluate a possible change in the fatigue experienced by the patients. In the treated cohort all measured variables, that is, fatigue score, quality of life, sleepiness, depression, cognition, and disability progression were improved from baseline (all p values<0.0001). Walking speed as measured by the six-minute walk-test also increased at month 12 (p = 0.0016). All patients were aware of the nature of the treatment agent, and of the study outcomes.

Conclusion: Natalizumab, as used in a real-life setting, might improve MS-related fatigue based on the results from this one-armed un-controlled stud. Also other parameters related to patients' quality of life seemed to improve with natalizumab treatment.

Place, publisher, year, edition, pages
Public Library Science , 2013. Vol. 8, no 3, e58643- p.
National Category
URN: urn:nbn:se:umu:diva-68478DOI: 10.1371/journal.pone.0058643ISI: 000316546400008OAI: diva2:618156
Available from: 2013-04-26 Created: 2013-04-22 Last updated: 2013-04-26Bibliographically approved

Open Access in DiVA

Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis: Results from the TYNERGY Trial: A Study in the Real Life Setting(491 kB)238 downloads
File information
File name FULLTEXT02.pdfFile size 491 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Svenningsson, Anders
By organisation
Clinical Neuroscience
In the same journal

Search outside of DiVA

GoogleGoogle Scholar
Total: 238 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 71 hits
ReferencesLink to record
Permanent link

Direct link